Imidazopyridine

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Imidazo[1,2-a]pyridine—an example of imidazopyridine and a core structure of zolpidem and some compounds described below.
Imidazo[1,2-a]pyridine—an example of imidazopyridine and a core structure of zolpidem and some compounds described below.

The imidazopyridines are a class of drugs defined by their chemical structure. In general, they are GABAA receptor agonists, however recently proton pump inhibitors, aromatase inhibitors, NSAIDs and other classes of drugs in this class have been developed as well. Despite usually being similar to them in effect, they are not chemically related to benzodiazepines. As such, GABAA-agonizing imidazopyridines, pyrazolopyrimidines, and cyclopyrrones are sometimes grouped together and referred to as "nonbenzodiazepines." Imidazopyridines include:

Anxiolytics, sedatives and hypnotics (GABAA receptor positive allosteric modulators):

Antipsychotics:

  • Imidazo[1,2-a]pyridines:
    • Mosapramine (brand name クレミン, Cremin)—an atypical antipsychotic used in Japan.[3]

Drugs used for peptic ulcer disease (PUD), GERD and gastroprokinetic agents (motility stimulants):

NSAIDs, analgesics and antimigraine drugs:

Drugs acting on the cardiovascular system:

Drugs for treatment of bone diseases:

Antineoplastic agents:

References[edit]

  1. ^ Wafford, KA; van Niel, MB; Ma, QP; Horridge, E; Herd, MB; Peden, DR; Belelli, D; Lambert, JJ (January 2009). "Novel Compounds Selectively Enhance Delta Subunit Containing GABA A Receptors and Increase Tonic Currents in Thalamus". Neuropharmacology 56 (1): 182–9. PMID 18762200. 
  2. ^ David J. Triggle (1996). Dictionary of Pharmacological Agents. Boca Raton: Chapman & Hall/CRC. ISBN 0-412-46630-9. 
  3. ^ Takahashi, N; Terao, T; Oga, T; Okada, M (1999). "Comparison of Risperidone and Mosapramine Addition to Neuroleptic Treatment in Chronic Schizophrenia". Neuropsychobiology 39 (2): 81–5. PMID 10072664. 
  4. ^ Mikami, T; Ochi, Y; Suzuki, K; Saito, T; Sugie, Y; Sakakibara, M (April 2008). "5-Amino-6-chloro-N-[(1-isobutylpiperidin-4-yl)methyl]-2-methylimidazo[1,2-alpha]pyridine-8-carboxamide (CJ-033,466), a Novel and Selective 5-hydroxytryptamine-4 Receptor Partial Agonist: Pharmacological Profile in vitro and Gastroprokinetic Effect in Conscious Dogs". The Journal of Pharmacology and Experimental Therapeutics 325 (1): 190–9. PMID 18198343. 
  5. ^ Belohlavek, D; Malfertheiner, P (1979). "The Effect of Zolimidine, Imidazopyridine-derivate, on the Duodenal Ulcer Healing". Scandinavian Journal of Gastroenterology. Supplement. 54: 44. PMID 161649. 
  6. ^ Kahrilas, PJ; Dent, J; Lauritsen, K; Malfertheiner, P; Denison, H; Franzén, S; Hasselgren, G (December 2007). "A Randomized, Comparative Study of Three Doses of AZD0865 and Esomeprazole for Healing of Reflux Esophagitis". Clinical Gastroenterology and Hepatology 5 (12): 1385–91. PMID 17950677. 
  7. ^ Ravinder Reddy, B; Basavaraja, H S; Shivaprasad LV J, S. "Reversible Proton Pump Inhibitors: A Superior Edge — Features". Pharmabiz.com. Saffron Media Pvt. Ltd I. Retrieved 7 December 2015. 
  8. ^ Merck Announces Second Quarter 2011 Financial Results
  9. ^ Uemura Y, Tanaka S, Ida S, Yuzuriha T (December 1993). "Pharmacokinetic Study of Loprinone Hydrochloride, a New Cardiotonic Agent, in Beagle Dogs". J. Pharm. Pharmacol. 45 (12): 1077–81. doi:10.1111/j.2042-7158.1993.tb07184.x. PMID 7908977. 
  10. ^ Shridhar Hegde; Michelle Schmidt (2009). "To Market, To Market - 2009. 16. Minodronic acid". Annual Reports in Medicinal Chemistry 45: 509–510. doi:10.1016/s0065-7743(10)45028-9.